FibroGen Inc (FGEN) CEO Sells $2,720,724.60 in Stock
FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 48,180 shares of the company’s stock in a transaction dated Friday, February 8th. The stock was sold at an average price of $56.47, for a total transaction of $2,720,724.60. Following the completion of the sale, the chief executive officer now directly owns 2,680,346 shares of the company’s stock, valued at $151,359,138.62. The sale was disclosed in a filing with the SEC, which is accessible through this link.
FibroGen stock opened at $56.98 on Monday. FibroGen Inc has a twelve month low of $37.27 and a twelve month high of $68.55. The company has a market cap of $4.84 billion, a PE ratio of -32.94 and a beta of 1.77. The company has a quick ratio of 6.76, a current ratio of 6.76 and a debt-to-equity ratio of 0.20.
FibroGen (NASDAQ:FGEN) last released its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.15). FibroGen had a negative net margin of 87.84% and a negative return on equity of 24.59%. The company had revenue of $29.00 million for the quarter, compared to the consensus estimate of $36.48 million. FibroGen’s quarterly revenue was down 28.6% on a year-over-year basis. On average, equities analysts expect that FibroGen Inc will post -1.55 EPS for the current fiscal year.
A number of equities research analysts have issued reports on FGEN shares. Leerink Swann set a $84.00 price objective on shares of FibroGen and gave the stock a “buy” rating in a research report on Monday, October 15th. BidaskClub raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. Zacks Investment Research downgraded shares of FibroGen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. Mizuho reaffirmed a “buy” rating and issued a $74.00 price objective on shares of FibroGen in a research report on Monday, December 17th. Finally, TheStreet downgraded shares of FibroGen from a “c-” rating to a “d+” rating in a research report on Wednesday, November 21st. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $70.25.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Featured Story: Net Margin
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.